This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Amazon plans to launch its first prototype satellites for Project Kuiper, an internet-from-space venture, in 2022. It's the first major step in the e-commerce giant's plan to rival SpaceX by building a network of satellites in space, providing internet to rural, underserved communities around the world. Loren Grush, senior science reporter for the Verge, discusses the project and how it could transform internet access moving forward.
The FDA is assessing whether the Moderna vaccine can cause heart problems in adolescents. Professor Peter Pitts, founder of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, discusses what the FDA is looking into and what it means for the millions of kids yet to be vaccinated.
Pfizer posted an earnings beat in its third quarter, with revenue soaring over 134% thanks to solid Covid-19 vaccine sales. Pfizer also raised its outlook for the full-year, expecting revenue to surpass $80 billion. Peter Andersen, CEO & founder of Andersen Capital Management, joined Cheddar Movers to discuss.
Cheddar gets a look at Curiosity Stream's 'Ancient Oceans'; Deep-sea biologist Heather Bracken-Grissom sheds light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths; Tim Janssen, CEO of Sofar Ocean, discusses Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Tim Janssen, CEO of Sofar Ocean, joins 'Cheddar Reveals' to discuss Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Deep-sea biologist Heather Bracken-Grissom joins 'Cheddar Reveals' to shed light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths.
Leaders around the world have come together to discuss plans to bring action towards the Paris Agreement along with solutions on how to solve the evolving climate change crisis at the COP26 Summit. President and CEO of Center for International Environmental Law Carroll Muffett, joined Cheddar to discuss more.
Rachel Cleetus, the policy director and lead economist of the climate and energy program for the Union of Concerned Scientists, joined Cheddar to break down some of the key goals from the COP26 summit and why leaders must focus on the science of climate change instead of getting bogged down by petty politics and the fossil fuel industry. "The main thing they have to do, make sure we're cutting our emissions sharply within this decade because the science shows that we have to cut global emissions in half by 2030 if we're going to meet our goals of averting some of the most catastrophic impacts of climate change," she said.
Coastal cities around the world are grappling with sea level rise. And building a seawall? Not so fast. While a sea wall can be effective in certain scenarios, it can make the effects of sea level rise worse. That’s why municipalities are looking into creative alternatives.
